Societal Merit of Intervention on Hearing Loss Evaluation
Launched by RADBOUD UNIVERSITY MEDICAL CENTER · Aug 30, 2022
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the long-term effects of cochlear implants (CIs) on people with progressive hearing loss, specifically those who have trouble hearing due to damage to the inner ear. The researchers want to see how getting a cochlear implant can improve various aspects of life, such as communication, independence, work performance, and overall quality of life. They will also look at how the waiting time for surgery affects these outcomes.
To participate, you need to be an adult who is eligible for a cochlear implant according to specific guidelines and willing to join the study. The trial is open to individuals aged 65 and older, as well as those younger than 65. However, certain individuals, like children, people with complex medical issues, or those who can't work for reasons unrelated to hearing, will not be included. If you join, you can expect to undergo assessments about your hearing and daily activities before and after receiving a cochlear implant, helping researchers understand how this intervention can make a difference in your life.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults (potentially) eligible for CI according to the Dutch quality standard for CI (Veldnorm CI 2013) and willing to participate. Participants are divided in 2 age categories (under and over 65 years old)
- Exclusion Criteria:
- • People with a complex syndrome with multiple problems.
- • Incapable of performing paid or unpaid labor, due to non-hearing related factors
- • Prelingual onset of deafness.
- • Children 0 - 18 years old.
- • Non-native Dutch speakers.
- • Patients suffering from a psychiatric disorder
- • Any condition that may hamper a complete insertion of the electrode array or a normal rehabilitation with the cochlear implant (severe otosclerosis or neurologic deficits)
About Radboud University Medical Center
Radboud University Medical Center is a leading academic medical institution located in Nijmegen, the Netherlands, dedicated to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, Radboud UMC leverages its multidisciplinary expertise to conduct high-quality research that aims to improve patient outcomes and enhance medical knowledge. The center is committed to ethical standards and regulatory compliance, fostering collaboration among researchers, healthcare professionals, and patients to translate scientific discoveries into effective clinical applications. With a focus on personalized medicine and cutting-edge technologies, Radboud University Medical Center plays a pivotal role in shaping the future of healthcare through its rigorous clinical trial initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Utrecht, , Netherlands
Nijmegen, Gelderland, Netherlands
Maastricht, Limburg, Netherlands
Amsterdam, Noord Holland, Netherlands
Leiden, Zuid Holland, Netherlands
Patients applied
Trial Officials
Emmanuel Mylanus
Study Director
Radboud University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials